Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts
This trial is active, not recruiting.
|Treatment||inhaled nitric oxide (ino)|
|Sponsor||Baylor Research Institute|
|Start date||July 2010|
|End date||November 2014|
|Trial size||2 participants|
|Trial identifier||NCT01172691, 010-085|
This study is being done to determine if patients receiving (iNO) will have increased liver function and less damage from IR than patients who do not receive (iNO).
|Endpoint classification||safety/efficacy study|
|Intervention model||parallel assignment|
|Masking||double blind (subject, investigator, outcomes assessor)|
Evaluate the role of iNO in early ischemia reperfusion injury in marginal liver grafts during human orthotopic liver or liver/kidney transplantation.
time frame: 24 hours to 1 month
iNO group will show accelerated restoration of liver allograft function following liver transplantation and this may translate to better clinical outcomes. Marginal grafts may function better in the treated group
time frame: 1 month to 1 year
Male or female participants from 17 years up to 70 years old.
Inclusion Criteria: - Liver Transplant Exclusion Criteria: - Living donor transplants
|Official title||Randomized, Blinded, Controlled Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts.|
|Principal investigator||Michael A Ramsay, MD|
Call for more information